<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="10830"><DrugName>BAY-17-1998</DrugName><DrugSynonyms><Name><Value>BAY-17-1998</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>BAY-35-8535</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="25345">Arris Pharmaceutical Corp</CompanyOriginator><CompaniesSecondary><Company id="14455">Bayer AG</Company><Company id="25345">Arris Pharmaceutical Corp</Company></CompaniesSecondary><CrossReferences><SourceEntity id="10830" type="Drug"><TargetEntity id="241363" type="siDrug">Bay-17-1998</TargetEntity></SourceEntity><SourceEntity id="14455" type="Company"><TargetEntity id="4295869217" type="organizationId">Bayer AG</TargetEntity></SourceEntity><SourceEntity id="25345" type="Company"><TargetEntity id="4295905654" type="organizationId">Axys Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="189" type="ciIndication"><TargetEntity id="10021972" type="MEDDRA"></TargetEntity><TargetEntity id="D015212" type="MeSH"></TargetEntity><TargetEntity id="-156308446" type="omicsDisease"></TargetEntity><TargetEntity id="394" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="291" type="ciIndication"><TargetEntity id="10039073" type="MEDDRA"></TargetEntity><TargetEntity id="D001172" type="MeSH"></TargetEntity><TargetEntity id="-1391695545" type="omicsDisease"></TargetEntity><TargetEntity id="749" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="31" type="ciIndication"><TargetEntity id="J45" type="ICD10"></TargetEntity><TargetEntity id="493" type="ICD9"></TargetEntity><TargetEntity id="10003553" type="MEDDRA"></TargetEntity><TargetEntity id="D001249" type="MeSH"></TargetEntity><TargetEntity id="-1473716268" type="omicsDisease"></TargetEntity><TargetEntity id="270" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="477" type="ciIndication"><TargetEntity id="10039083" type="MEDDRA"></TargetEntity><TargetEntity id="D012220" type="MeSH"></TargetEntity><TargetEntity id="-535061555" type="omicsDisease"></TargetEntity><TargetEntity id="297" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="77" type="ciIndication"><TargetEntity id="H10" type="ICD10"></TargetEntity><TargetEntity id="10010741" type="MEDDRA"></TargetEntity><TargetEntity id="D003231" type="MeSH"></TargetEntity><TargetEntity id="-150010834" type="omicsDisease"></TargetEntity><TargetEntity id="762" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity></SourceEntity><SourceEntity id="724" type="Action"><TargetEntity id="509" type="Mechanism">Tryptase Inhibitors</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="189">Inflammatory bowel disease</Indication><Indication id="291">Rheumatoid arthritis</Indication><Indication id="31">Asthma</Indication><Indication id="477">Rhinitis</Indication><Indication id="77">Conjunctivitis</Indication></IndicationsSecondary><ActionsPrimary><Action id="724">Tryptase inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="2953">Anti-inflammatory</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2017-08-28T10:14:06.000Z</LastModificationDate><ChangeDateLast>2009-07-29T14:42:30.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;Under their R&amp;amp;D agreement, Arris and &lt;ulink linkID="14455" linkType="Company"&gt;Bayer&lt;/ulink&gt; are developing drugs that block the activity of tryptase for the potential treatment of asthma, rhinitis, conjunctivitis, rheumatoid arthritis and inflammatory bowel disease. &lt;/para&gt;&lt;para&gt;The lead compound was &lt;ulink linkID="10830" linkType="Drug"&gt;Bay-17-1998&lt;/ulink&gt; (also designated Bay-35-8535), which had been expected to enter clinical trials for asthma in 1997 [&lt;ulink linkID="254806" linkType="reference"&gt;254806&lt;/ulink&gt;]. However, in June 1998, &lt;ulink linkID="14455" linkType="Company"&gt;Bayer&lt;/ulink&gt; discontinued its part in the development of &lt;ulink linkID="10830" linkType="Drug"&gt;Bay-17-1998&lt;/ulink&gt; in order to focus on the continued development of &lt;ulink linkID="8109" linkType="Drug"&gt;APC-366&lt;/ulink&gt; (qv) [&lt;ulink linkID="288549" linkType="reference"&gt;288549&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt; &lt;ulink linkID="10830" linkType="Drug"&gt;Bay-17-1998&lt;/ulink&gt;, an inhaled tryptase inhibitor, is a second generation drug to &lt;ulink linkID="8109" linkType="Drug"&gt;APC-366&lt;/ulink&gt;, and shows a higher potency and selectivity profile [&lt;ulink linkID="247587" linkType="reference"&gt;247587&lt;/ulink&gt;]. It was designed with the aid of Arris's Delta technology, which allows the design of potent and selective serine and cysteine protease inhibitors with the characteristics of oral drugs, ie low molecular weight, simple (non-peptidic) structures and a competitive reversible action [&lt;ulink linkID="247587" linkType="reference"&gt;247587&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="477">Rhinitis</Indication><StatusDate>1998-06-03T00:00:00.000Z</StatusDate><Source id="288549" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="25345">Arris Pharmaceutical Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="477">Rhinitis</Indication><StatusDate>1998-06-03T00:00:00.000Z</StatusDate><Source id="288549" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>1998-06-03T00:00:00.000Z</StatusDate><Source id="288549" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="25345">Arris Pharmaceutical Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>1998-06-03T00:00:00.000Z</StatusDate><Source id="288549" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="77">Conjunctivitis</Indication><StatusDate>1998-06-03T00:00:00.000Z</StatusDate><Source id="288549" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="189">Inflammatory bowel disease</Indication><StatusDate>1998-06-03T00:00:00.000Z</StatusDate><Source id="288549" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="25345">Arris Pharmaceutical Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="189">Inflammatory bowel disease</Indication><StatusDate>1998-06-03T00:00:00.000Z</StatusDate><Source id="288549" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="31">Asthma</Indication><StatusDate>1998-06-03T00:00:00.000Z</StatusDate><Source id="288549" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="25345">Arris Pharmaceutical Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="31">Asthma</Indication><StatusDate>1998-06-03T00:00:00.000Z</StatusDate><Source id="288549" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="25345">Arris Pharmaceutical Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="77">Conjunctivitis</Indication><StatusDate>1998-06-03T00:00:00.000Z</StatusDate><Source id="288549" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="77">Conjunctivitis</Indication><StatusDate>1995-09-08T00:00:00.000Z</StatusDate><Source id="180465" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="477">Rhinitis</Indication><StatusDate>1995-09-08T00:00:00.000Z</StatusDate><Source id="180465" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="31">Asthma</Indication><StatusDate>1995-09-08T00:00:00.000Z</StatusDate><Source id="180465" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>1995-09-08T00:00:00.000Z</StatusDate><Source id="180465" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="189">Inflammatory bowel disease</Indication><StatusDate>1995-09-08T00:00:00.000Z</StatusDate><Source id="180465" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25345">Arris Pharmaceutical Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="189">Inflammatory bowel disease</Indication><StatusDate>1995-09-08T16:09:26.000Z</StatusDate><Source id="180465" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25345">Arris Pharmaceutical Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>1995-09-08T16:09:26.000Z</StatusDate><Source id="180465" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25345">Arris Pharmaceutical Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="77">Conjunctivitis</Indication><StatusDate>1995-09-08T16:09:26.000Z</StatusDate><Source id="180465" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25345">Arris Pharmaceutical Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="477">Rhinitis</Indication><StatusDate>1995-09-08T16:09:26.000Z</StatusDate><Source id="180465" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25345">Arris Pharmaceutical Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="31">Asthma</Indication><StatusDate>1995-09-08T16:09:26.000Z</StatusDate><Source id="180465" type="CORPORATE"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-01897"><Name>Tryptase</Name><SwissprotNumbers/></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="14455">Bayer AG</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="DOL1000590">Quest Diagnostics Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>0</CountActive><CountInactive>1</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="127338" title="Arris and Bayer to codevelop tryptase and chymase inhibitors worldwide"/></Deals><hasSWOTs>N</hasSWOTs></drugRecordOutput>